



12 August 2020

Creso signs agreement with DHS Business for entrance into the Iberic markets with its CBD products

Highlights:

- **Creso signs a commercial agreement with DHS Business/Lisbon to introduce their products into the Portuguese and Spanish markets**
- **Among the key products to be launched will be Creso's cannaDOL® CBD topical gels and cannaQIX oral care Swiss Made**
- **This will expand Creso's presence in Europe**

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to inform that it signed a commercial agreement with DHS Business Portugal to introduce Creso's products into the Portuguese and Spanish markets.

In conjunction with DHS Business, Creso intends to focus first products focus on cannaDOL® 0.5% and 1% CBD topical gels to support the improvement of mobility. These products target the sports population but also the population with diminished mobility due to Rheumadoid Arthritis and Arthrosis.

Further, Creso will also consider products sales of cannaQIX ®oral care addressing the needs of stress reduction and providing benefits for oral care management.

Creso and DHS Business aim to achieve a major coverage of sports shops and pharmacies offering over 2,000 points of sales in Portugal and over 4,000 points of sales in Spain. First focus will be on the major cities Lisbon, Sintra, Porto (>4.5 M) in Portugal. In Spain, the focus will be on Madrid, Barcelona, Valencia and Sevilla (Total population > 6.2 M). With the products, Creso and DHS Business aim to target the sports working and aging population representing approximately 50% of the total population (=3.8 M).

Under the terms of the agreement, DHS Business will be paid an industry standard commission on sales of products. No other fees were paid, or are payable, to any other party in relation to the agreement.

The agreement has an indefinite term, but may be terminated by 30 days notice by either party or forthwith for material breach.



cannaDOL®0.5%, 1% 100 ml gel tubes



cannaQIX® oral care

Management Commentary

Creso Commercial Director Jorge Wernli, commented: “We are very much looking forward to enter the Portuguese and Spanish markets with our Creso topical and oral care products. These markets are very attractive supporting us for further expansion into Latin America.”

Next Steps

Creso and DHS Business are working on implementation plans, with a view to first products being sold in Spain/Portugal in Q1 2021.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Creso Board

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

**Released through:**

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

About DHS

DHS is active in the healthcare markets since 1991 and involved in strategic consulting and commercialization operations in Brazil, Latin America, USA, Africa (Angola, Mozambique) and Portugal. DHS is a global solution provider for companies in the Health and Wellness market, looking to expand Brazilian company business and better support the foreign companies targeting business through their Latin & North America network. Among the local and international customers count ICU Medical Inc., Elcam Medical, Medcaptain Medical Technology, Co, Grupo MPR, BSAF de Oliveira, Forever Wireless Ltd., Allplats Ltda, Europe, 4W Sites Ltda., for whom DHS is providing planning, management, product registration, distributor prospecting and selection, forecasting, trade negotiations, and operational support for Brazilian and International business.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.